<DOC>
	<DOCNO>NCT02982005</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety KHK4827 subject moderate severe plaque psoriasis randomize double-blind manner receive KHK4827 placebo 12 week</brief_summary>
	<brief_title>A Study KHK4827 ( Brodalumab ) Subjects With Moderate Severe Psoriasis Korea</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject stable moderate severe plaque psoriasis least 6 month Subject involve BSA ≧ 10 % , PASI ≧ 12 , sPGA ≧ 3 screen baseline Subject diagnose erythrodermic psoriasis , pustular psoriasis , guttate psoriasis , medicationinduced psoriasis , skin condition ( e.g. , eczema ) screen would interfere study evaluation Subject schedule undergo surgical intervention study period Subject active infection history infection define study protocol Subject know history Crohn 's disease Subject significant concurrent medical condition laboratory abnormality , define study protocol Subject stop use certain psoriasis therapy define study protocol Subject previously use antiIL17 biologic therapy Subject pregnant breast feeding , plan become pregnant enrol study Women childbearing potential fertile men agree use effective contraception day provide consent 12 week last dose investigational product . Subject known history evidence suicidal ideation ( severity 4 5 ) suicidal behavior base assessment ColumbiaSuicide Severity Rating Scale ( CSSRS ) screen baseline Subject severe depression base total score ≥ 15 Patient Health Questionnaire8 ( PHQ8 ) screen baseline Subject know history evidence psychiatric disorder , opinion investigator , would pose risk subject safety interfere study evaluation , procedures completion Subject know history alcohol and/or substance abuse within last 12 month ''</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>KHK4827 ( brodalumab )</keyword>
</DOC>